Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio

被引:6
|
作者
Yip, Steven M. [1 ]
Kaiser, Jeenan [1 ]
Li, Haocheng [2 ,3 ]
North, Scott [4 ]
Heng, Daniel Y. C. [1 ]
Alimohamed, Nimira S. [1 ]
机构
[1] Univ Calgary, Dept Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada
[2] Univ Calgary, Dept Oncol, Calgary, AB, Canada
[3] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
[4] Univ Alberta, Dept Oncol, Cross Canc Inst, Edmonton, AB, Canada
关键词
Metastatic urothelial carcinoma; Neutrophil to lymphocyte ratio (NLR); Outcomes; TCC; Transitional cell; INVASIVE BLADDER-CANCER; PHASE-III TRIAL; 1ST-LINE CHEMOTHERAPY; MEDICAL ONCOLOGISTS; CARCINOMA PATIENTS; CISPLATIN; SURVIVAL; THERAPY; VINFLUNINE; FAILURE;
D O I
10.1016/j.clgc.2017.12.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the first- and second-line metastatic urothelial carcinoma (mUC) treatment setting, we investigated realworld outcomes and evaluated the prognostic role of neutrophil to lymphocyte ratio (NLR). A retrospective analysis was performed on 233 mUC patients. In this real-world mUC analysis, first-line outcomes were lower than expected. Low NLR in the first- and second-line is associated with improved mTTF and mOS. Introduction: In the first- and second-line metastatic urothelial carcinoma (mUC) treatment setting, we investigated real-world outcomes and evaluated the prognostic role of neutrophil to lymphocyte ratio (NLR). Methods: A retrospective analysis was performed on patients with mUC treated with systemic therapy. Overall response rates (ORRs), median time to treatment failure (mTTF), and median overall survival (mOS) were calculated. The association between baseline NLR (using a literature-derived cut-off of 3, as well as the best cut-off NLR value of 5.45 as identified by X-Tile software from this dataset) and mTTF and mOS were evaluated using Cox regression analysis. Results: We evaluated 233 patients. In the first-line, the ORR was 25%. mTTF and mOS were 6.9 months and 9.0 months, respectively. Low baseline NLR was significantly associated with improved 8.3-month mTTF, in contrast to 5.8 months for patients with high NLR (P = .046). Low NLR was significantly correlated with a longer mOS of 13.1 months, compared with high NLR (8.2 months; P = .007). In the second-line, an ORR of 22%, an mTTF of 4.1 months, and an mOS of 8 months were observed. Low NLR in the second-line was significantly associated with improved mTTF at 7.9 months versus high NLR patients (3.3 months; P = .023). Second-line low NLR was significantly associated with a longer mOS of 12.2 months, in comparison to 6.8 months with high NLR (P = .003). Conclusion: In this real-world analysis of patients with mUC, first-line outcomes were lower than expected. Low NLR in the first- and second-line is associated with improved mTTF and mOS. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:E637 / E644
页数:8
相关论文
共 50 条
  • [1] Real world outcomes in advanced urothelial cancer and the role of neutrophil to lymphocyte ratio
    Yip, Steven
    Kaiser, Jeenan
    Li, Haocheng
    North, Scott A.
    Heng, Daniel Yick Chin
    Alimohamed, Nimira S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Real-world survival outcomes in patients with advanced urothelial cancer in Germany
    Niegisch, G.
    Gerullis, H.
    Lin, S-W.
    Pavlova, J.
    Gondos, A.
    Rudolph, A.
    Haas, G.
    Hennies, N.
    Kramer, M. W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] Effect of neutrophil to lymphocyte ratio (NLR) on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in real-world setting.
    Lynn, David
    Dawsey, Scott
    Patgunarajah, Ubenthira
    Pramod, Nikhil
    Wei, Wei
    Hobeika, Charbel
    Nair, Monica
    Maroli, Kimberly
    Martin, Allison
    Ornstein, Moshe Chaim
    Wee, Christopher Eing
    Gilligan, Timothy D.
    Nizam, Amanda
    Bonham, Amanda
    Mian, Omar Y.
    Pavicic, Paul G.
    Diaz-Montero, C. Marcela
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 678 - 678
  • [4] The Role of Epicardial Fat Thickness and Neutrophil-to-Lymphocyte Ratio Are Needed to Be Studied in Real-World Stroke Patients
    Altun, Ibrahim
    Akin, Fatih
    Biteker, Murat
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2015, 24 (05): : 1100 - 1100
  • [5] Role of derived neutrophil lymphocyte ratio as a biomarker in advanced colorectal cancer
    Seligmann, Jenny
    Hall, Peter
    Wilson, Harriet
    Richman, Susan
    Barrett, Jenny
    Seymour, Matthew
    Quirke, Philip
    LANCET, 2014, 383 : 96 - 96
  • [6] Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC).
    Barata, Pedro C.
    Gopalakrishnan, Dharmesh
    Elson, Paul
    Koshkin, Vadim S.
    Ornstein, Moshe Chaim
    Diaz-Montero, C. Marcela
    Haywood, Samuel
    Rayman, Patricia A.
    Finke, James
    Lamenza, Marcelo
    Devonshire, Sarah
    Profusek, Pam
    Allman, Kimberly D.
    Martin, Allison
    Beach, Jennifer
    Schach, Kim
    Gilligan, Timothy D.
    Rini, Brian I.
    Garcia, Jorge A.
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer
    W Chua
    K A Charles
    V E Baracos
    S J Clarke
    British Journal of Cancer, 2011, 104 : 1288 - 1295
  • [8] Neutrophil - lymphocyte ratio (NLR) as a biomarker in urothelial bladder cancer
    Bora, G. S.
    Chandna, A.
    Kumar, S.
    Kakkar, N.
    Singh, S.
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 : 8 - 8
  • [9] Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer
    Chua, W.
    Charles, K. A.
    Baracos, V. E.
    Clarke, S. J.
    BRITISH JOURNAL OF CANCER, 2011, 104 (08) : 1288 - 1295
  • [10] Dynamic changes in neutrophil-to-lymphocyte ratio of head and neck cancer patients receiving nivolumab in a real-world setting
    Cabezas-Camarero, S.
    Gutierrez Abad, D.
    Ugidos de la Varga, L.
    Corral Jaime, J.
    Perez-Segura, P.
    ANNALS OF ONCOLOGY, 2019, 30